ALZHEIMER

A Houston artist is shedding light on the darkness of Alzheimer’s with a two-day event, being held on Tuesday and Saturday.

An Alzheimer’s patient in Japan who says he cannot remember killing his granddaughter nearly two years ago has been sentenced to four and a half years in prison. Susumu Tomizawa, 88, got into an argument with his 16-year-old granddaughter, Tomomi, in their home in Fukui Prefecture on Sept. 9, 2020. On the same night, he took a 6.69-inch-long kitchen knife and went into her bedroom, where he repeatedly stabbed her in the neck.

A massive fire in a nursing home for Alzheimer patients in the Czech Republic has left two people dead and injured more than 50 others

A search is underway for a woman who went missing Tuesday while walking her dog in a Katy area neighborhood, according to Texas EquuSearch.

Here are 10 early signs and symptoms of Alzheimer's, according to the Alzheimer's Association. If you notice any of these signs in a loved one, schedule an appointment with their doctor.

The drug, aducanumab, works by sticking antibodies to plaques in the brain, allowing the body's immune system to come in and remove them.

Police and family members are asking for the public’s help in finding a 79-year-old man suffering from Alzheimer’s who they said has been missing since Sunday.

On Monday's show: Identifying new coronavirus variants and drug-resistant bacteria, how news organizations cover COVID-19, and an Alzheimer's expert answers your questions.

Biogen drug, the first in decades approved to treat the disease, has sparked concerns about its high cost and efficacy.

Biogen drug, the first in decades approved to treat the disease, has sparked concerns about its high cost and efficacy.

Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.

Drugmaker said it will cut wholesale cost of drug by 50% next month, which translates to $28,200 a year for patient.

America’s drug regulators have been without a permanent commissioner for almost a year. The problems are piling up.

Eric Zemmour's poll ratings have faded since a splashy entrance into the French presidential campaign

Dr. Reisa Sperling, director at the Center for Alzheimer’s Research and Treatment at the Brigham and Women’s Hospital, said there’s increasing information that links lifestyle to Alzheimer’s.

The City of Laredo Mayor Pete Saenz proclaimed National Caregivers and Alzheimer’s...

How to get help and steps to take.

Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, joins CBS News from Pittsburgh to discuss COVID hospitalizations, vaccines for children and booster shots.

More than six million Americans are living with Alzheimer's, according to the Alzheimer's Association.

Guest: Dr. Steven Starks

“Ghosts” considers the difficulty of finding Mr. Right while taking care of an ailing parent.

Studies presented at an Alzheimer’s Association conference this week, not yet peer-reviewed, emphasize the need for vaccination, an association vice president said. “The best advice is don’t get covid.”

Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.

The confirmed death toll rose to 79 on Friday after additional victims were recovered.

Acting commissioner Janet Woodcock said there are "ongoing interest and questions" about how FDA cleared the drug for use.

Featuring splurge-worthy items to feed your design obsession Originally Appeared on Architectural Digest

Eli Lilly says it will submit its potential Alzheimer’s treatment to federal regulators later this year.

A new drug, Aducanumab, was approved by the FDA earlier this month. It allegedly slows the rate of Alzheimer’s progress.

Some don’t want the Advance Research Projects Agency for Health to be based inside the National Institutes of Health.

Dr. Aaron Kesselheim warned "there is a lot of evidence" the drug causes side effects and called the FDA's approval the "wrong decision."

Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the worst drug approval decision in recent US history."

A new report says the $56,000 Alzheimer’s drug approved this week would raise Medicare premiums broadly.

Colorado University School of Medicine plans to enroll participants in a Phase 4 study of the new Alzheimer's drug.

The company said is it charging $56,000 for an annual course of the treatment, higher than the $10,000 to $25,000 price some analysts were expecting.

The new medicine is made from living cells that will have to be given via infusion at a doctor's office or hospital.

Sanjay Gupta's prescription for fighting off dementia The neurosurgeon, CNN commentator and author of "Keep Sharp: Build a Better Brain at Any Age" has long studied the brain and the onset of Alzheimer's. He talks with CBS News chief medical correspondent Dr. Jon LaPook about the recommended steps to a healthier brain, from diet and exercise to the value of sleep and social interaction.

HOUSTON – A former Major League Baseball pitcher with Alzheimer’s has been found safe Thursday afternoon near the Astrodome area, police confirmed. Roric Harrison, 74, went missing on Wednesday off Main Street in the Texas Medical Center. Police said he was found by a good Samaritan and is safely back home with his family. Police said Harrison was a pitcher in Major League Baseball for five years back in the 1970s. Harrison, who was signed to the Houston Astros at a point in his career, was the last American League pitcher to hit a home run in an American League game before they introduced the designated hitter.

A Food and Drug Administration panel on Friday unexpectedly declined to endorse Biogen's experimental Alzheimer's drug aducanumab in a setback for the pharmaceutical company. In an 8-1 vote, the panel said Biogen's late-stage study didn't provide "strong evidence" showing that aducanumab effectively treated Alzheimer's. Alzheimer's disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. The U.S. agency has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The FDA's final decision on Biogen's drug is expected by March.

Biogen's stock jumped 42% in midmorning trading Wednesday after the Food and Drug Administration staff said they have enough data to support approval of the company's experimental Alzheimer's drug Aducanumab. "Based on the considerations above, the applicant has provided substantial evidence of effectiveness to support approval," FDA staff said in a document reviewing the drug published on the agency's website. The FDA also said the drug has "an acceptable safety profile that would support use in individuals with Alzheimer's disease." The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The FDA's final decision on Biogen's drug is expected by March.

Update: Houston police located an elderly woman who had been reported missing Saturday. The Houston Police Department is searching for an elderly woman with Alzheimer’s reported missing in Houston. Gloria Saldana, 76, was last seen Friday leaving the 10100 block of Lost Trail St. in an unknown direction. Saldana is described as a Hispanic female weighing 104 pounds and standing 4′8′' tall with brown eyes and black and grey hair. Anyone with information on her whereabouts is urged to contact the Houston Police Patrol at (713) 884-3131 or the Houston Police Department Missing Persons Division at (832) 394-1840.

The Food and Drug Administration's call on whether to approve Biogen's experimental Alzheimer's drug, aducanumab, will be the "most important decision" the federal regulator will make in 2020, Bernstein analyst Ronny Gal said Friday. When asked if he thought the FDA would approve the drug, Gal said, "Yes." Biogen's drug targets a "sticky" compound in the brain known as beta-amyloid, which is hypothesized to play a role in the devastating disease. The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. However, some analysts are skeptical of whether Biogen's drug actually works after the company's apparent reversal on exploring FDA approval.

But others were dubious.Changes made during the study and unusual analyses of the data made the results hard to interpret. "It's hard to know exactly what happened here," said Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation. "The drug "is worthy of significant, rigorous exploration" and review by the FDA, she said. John Ioannidis, a Stanford University expert on research methods, said patients' need should not drive the FDA's decision. "If we go down that path, we're likely to introduce a lot of ineffective treatments for diseases that are really common," he said.

HOUSTON, Texas (KTRK) -- Should a Court of Appeals Justice remain on the job after an Alzheimer's diagnosis?That is the question at the heart of a family saga involving the mayor of West University Place and his entire family.When you walk into the stately First Court of Appeals courthouse in downtown Houston, Justice Laura Higley's smiling face is displayed along with the other justices.At the city hall of West University Place, her husband Bob Higley's picture is also on display, as its current mayor.However, it's the court filings in Harris County Probate Court 2 that paints the picture behind the smiling images. "The sons also accuse their own father, Mayor Bob Higley, as having "acted as a malevolent enabler in that he has encouraged Justice Higley not to resign or retire from serving as Justice in the First Court of Appeals. ""He's the mayor of West University, but obviously the sons feel like he has not done what he's supposed to do," said McCandless. "She should not be in that position. She needs to have proper care, and it must be very difficult for those sons to say, 'We have to take action.

Federal regulators may buckle to public and political pressure to approve Biogen's experimental Alzheimer's drug, aducanumab, Jefferies' Michael Yee told CNBC on Monday. Biogen's drug would be worth billions. Yee said regulators will likely face pleas from friends and family members of Alzheimer's patients asking for fast-track approval of the drug. But Yee, like many other analysts, is also skeptical of Biogen's new analysis of the drug. "We're more cautious on Biogen" and investors should be too, Yee said, claiming that Biogen's data on its drug is "murky."

Biotech firm Biogen could double its market cap on regulatory approval for its experimental Alzheimer's drug, aducanumab, CNBC's Jim Cramer said Wednesday. The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The stunning reversal from Biogen was initially met with deep skepticism from investors, but Cramer expects that will change. "I think they'll ultimately become believers because Biogen resumed work on this drug at the behest of the FDA," Cramer said. The stock has rallied 34% since it announced it was seeking approval for its Alzheimer's drug last week.

Biogen CEO Michel Vounatsos told CNBC on Wednesday that he is "reasonably confident" the U.S. Food and Drug Administration will approve the drugmaker's experimental Alzheimer's drug. "We worked in full transparency with the regulator," Vounatsos told "Squawk Box," emphasizing the FDA has all of the company's data on the drug. "This was a thorough engagement, and as CEO I'm reasonably confident this will lead to market approval one day." Shares of Biogen soared more than 26% on Tuesday after the drugmaker shocked investors by announcing it was seeking regulatory approval for its once failed Alzheimer's drug, aducanumab. Alzheimer's disease can cause people's memory and mind to deteriorate to the point where they cannot function on their own and eventually die.

Biogen on Tuesday made a surprising reversal on its Alzheimer's treatment with plans now to seek U.S. regulatory approval, after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. The drugmaker's shares soared 37% in premarket trade, erasing most of their losses this year that came after it abandoned two studies for the drug. Biogen and partner Eisai Co Ltd had in March decided to end two late-stage trials of aducanumab based on a so-called "futility analysis" of data, which revealed the trials had little hope of succeeding. The failure of the treatment, which was widely expected to be Biogen's next blockbuster treatment, spurred demands on Wall Street for it to spend more on product acquisitions at a time when its peers have splurged on billions of dollars in deals. The company said more data became available after the two studies were discontinued in March, resulting in a larger dataset and a new analysis showed that one of the trials met the main goal, while the other did not.

What happened when Russia hacked the United States' election infrastructure?; then, inside the memorial to victims of lynching; and, following a couple from diagnosis to the final stages of Alzheimer’s

Untangling the Facebook data scandal, Inside MIT's "Future Factory," For better or worse: Living with Alzheimer's Lesley Stahl reports on Aleksandr Kogan, the link between Facebook and Cambridge Analytica; then, Scott Pelley goes inside MIT's "Future Factory"; and, for better or worse, living with Alzheimer's

A new study finds high levels of stress may raise the risk of mild cognitive impairment, a condition that's often a precursor to Alzheimer's disease. CBS News' Marlie Hall reports.

A common hormone treatment for men with prostate cancer may raise their risk of developing Alzheimer's disease, a new study finds. CBS News' Omar Villafranca reports.

A new study says older people who walk more slowly may be more likely to develop Alzheimer's disease. CBS News' Kenneth Craig reports.

Local pharmacies, restaurants and other businesses are taking steps to be more welcoming and accommodate the needs of dementia patients and their families. WHIO-TV's Rachel Murray reports.

A new study from Duke University suggests women at risk for Alzheimer's face a steeper decline than men. CBS News chief medical correspondent Dr. Jon LaPook explains.

Researchers at Duke University may have found the cause of Alzheimer's disease. CBS News chief medical correspondent Dr. Jon LaPook explains.

Research out of Duke University suggests immune system irregularities may cause Alzheimer’s Disease - a revelation that, if true, could lead to new treatments.

New drug shows promise for helping Alzheimer's Researchers at Mount Sinai Hospital in New York are testing a new drug that they hope will slow the progression of Alzheimer's disease by protecting nerve cells in the brain. Alison Harmelin reports.

Siblings swim English Channel for Alzheimer's awareness Devin, Dustin and Danielle Wahl could be the first trio of siblings to swim across the English Channel at the same time. They're doing it in part to raise awareness about Alzheimer's, a disease that affected their loved ones. Norah O'Donnell reports.

Eye tests may help detect Alzheimer's Researchers announced a new technique that may help detect Alzheimer's decades before diagnosis. They're looking for signs of it in the most unusual place: the eye. Don Dahler reports.